NASDAQ:IRIX IRIDEX (IRIX) Stock Price, News & Analysis $1.02 -0.01 (-0.97%) Closing price 04/17/2025 03:58 PM EasternExtended Trading$0.93 -0.09 (-8.73%) As of 04/17/2025 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About IRIDEX Stock (NASDAQ:IRIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IRIDEX alerts:Sign Up Key Stats Today's Range$0.98▼$1.0450-Day Range$0.79▼$1.5552-Week Range$0.78▼$3.25Volume106,234 shsAverage Volume42,726 shsMarket Capitalization$17.12 millionP/E RatioN/ADividend YieldN/APrice Target$2.00Consensus RatingHold Company OverviewIRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.Read More… IRIDEX Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreIRIX MarketRank™: IRIDEX scored higher than 27% of companies evaluated by MarketBeat, and ranked 578th out of 654 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingIRIDEX has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageIRIDEX has received no research coverage in the past 90 days.Read more about IRIDEX's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of IRIDEX is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IRIDEX is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIRIDEX has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about IRIDEX's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.31% of the float of IRIDEX has been sold short.Short Interest Ratio / Days to CoverIRIDEX has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IRIDEX has recently increased by 5.17%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIRIDEX does not currently pay a dividend.Dividend GrowthIRIDEX does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.31% of the float of IRIDEX has been sold short.Short Interest Ratio / Days to CoverIRIDEX has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IRIDEX has recently increased by 5.17%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment0.27 News SentimentIRIDEX has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 4 news articles for IRIDEX this week, compared to 1 article on an average week.MarketBeat Follows1 people have added IRIDEX to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, IRIDEX insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.30% of the stock of IRIDEX is held by insiders.Percentage Held by InstitutionsOnly 20.10% of the stock of IRIDEX is held by institutions.Read more about IRIDEX's insider trading history. Receive IRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter. Email Address IRIX Stock News HeadlinesStockNews.com Begins Coverage on IRIDEX (NASDAQ:IRIX)April 18 at 2:37 AM | americanbankingnews.comIRIDEX Corporation: Iridex Announces Preliminary Operational and Financial Results for the First Quarter 2025April 17 at 4:53 PM | finanznachrichten.deTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…April 20, 2025 | Paradigm Press (Ad)IRIDEX Corporation (IRIX) Strategic Vision Conference Call (Transcript)April 16, 2025 | seekingalpha.comIRIDEX (NASDAQ:IRIX) Now Covered by Analysts at StockNews.comApril 12, 2025 | americanbankingnews.comIridex to Host Strategic Vision Call on April 16, 2025April 9, 2025 | globenewswire.comIridex to Host Strategic Vision Call on April 16, 2025April 9, 2025 | globenewswire.comIRIDEX Corporation (NASDAQ:IRIX) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comSee More Headlines IRIX Stock Analysis - Frequently Asked Questions How have IRIX shares performed this year? IRIDEX's stock was trading at $1.68 at the start of the year. Since then, IRIX stock has decreased by 39.3% and is now trading at $1.02. View the best growth stocks for 2025 here. How were IRIDEX's earnings last quarter? IRIDEX Co. (NASDAQ:IRIX) released its earnings results on Thursday, March, 27th. The medical equipment provider reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05). The medical equipment provider had revenue of $12.70 million for the quarter, compared to analysts' expectations of $12.80 million. IRIDEX had a negative net margin of 22.79% and a negative trailing twelve-month return on equity of 192.95%. Read the conference call transcript. How do I buy shares of IRIDEX? Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IRIDEX own? Based on aggregate information from My MarketBeat watchlists, some other companies that IRIDEX investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Meta Platforms (META), CymaBay Therapeutics (CBAY), Arista Networks (ANET) and CrowdStrike (CRWD). Company Calendar Last Earnings3/27/2025Today4/20/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:IRIX CIK1006045 Webwww.iridex.com Phone(650) 940-4700Fax650-940-4710Employees120Year Founded1989Price Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+96.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,570,000.00 Net Margins-22.79% Pretax Margin-22.51% Return on Equity-192.95% Return on Assets-33.97% Debt Debt-to-Equity Ratio0.55 Current Ratio1.54 Quick Ratio0.85 Sales & Book Value Annual Sales$48.67 million Price / Sales0.35 Cash FlowN/A Price / Cash FlowN/A Book Value$0.59 per share Price / Book1.73Miscellaneous Outstanding Shares16,789,000Free Float15,422,000Market Cap$17.12 million OptionableOptionable Beta0.74 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:IRIX) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IRIDEX Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share IRIDEX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.